Dexcom reported preliminary, unaudited results for Q4 2025 with total revenue of $1.260 billion, up 13% from Q4 2024.
U.S. revenue reached approximately $892 million, indicating an 11% growth over Q4 2024.
The international revenue also showed strong growth, reaching about $368 million, up 18% from Q4 2024.
Revenue Growth
Total revenue for fiscal 2025 was $4.662 billion, a 16% increase over 2024.
2026 Outlook
Dexcom anticipates total revenue of $5.16 - $5.25 billion in 2026, expecting 11-13% growth over 2025.
Margins Projection
Non-GAAP Gross Profit Margin is estimated at 63 - 64% and Non-GAAP Operating Margin at 22 - 23% for 2026.
- Dexcom's strong revenue growth in 2025 showcases its ability to capture market opportunities and innovate in diabetes management.
- The outlook for 2026 suggests continued growth driven by CGM awareness, international expansion, and product advancements.
With a solid performance in 2025 and a promising outlook for 2026, Dexcom demonstrates resilience and innovation in the healthcare technology sector.